Glenmark Pharmaceuticals stock | Price, analyst rating, price target & growth

Glenmark Pharmaceuti...

NSEI:GLENMARK

Rp 2.131,70

Rp-38,80 (-1,79%)

2.131,70 Rp

Rp-38,80 (-1,79%)

End-of-day quote: 03/31/2026

Glenmark Pharmaceuticals Stock Value

Analysts currently give NSEI:GLENMARK a rating of Outperform.

Outperform

Glenmark Pharmaceuticals Company Info

EPS Growth 5Y

11,99%

Market Cap

Rp612,52 B

Long-Term Debt

Rp5,13 B

Annual earnings

05/23/2026 (E)

Dividend

Rp4,90

Dividend Yield

0,23%

Founded

1977

Industry

Health Care

Country

India

Website

Glenmark Pharmaceuticals

ISIN Number

INE935A01035

Website

http://www.glenmarkpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp2.270,00

6.49%

Last Update: 03/31/2026

Analysts: 12

Highest Price Target Rp2.735,00

Average Price Target Rp2.270,00

Lowest Price Target Rp1.500,00

In the last five quarters, Glenmark Pharmaceuticals’s Price Target has risen from Rp525,67 to Rp767,80 - a 46,06% increase. Eight analysts predict that Glenmark Pharmaceuticals’s share price will increase in the coming year, reaching Rp2.270,00. This would represent an increase of 6,49%.

Top growth stocks in the health care sector (5Y.)

What does Glenmark Pharmaceuticals do?

Glenmark Pharmaceuticals Limited develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products. Business Segments The company has distinct business segments that contribute to its overall operations. The primary segments include: Generics: The company operates a significant business in generics that focuses on developing generic pharmaceutical products for global markets. This segment showcases the company's capability in producing cost-effective, high-qualit...

Glenmark Pharmaceuticals Limited develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products.

Business Segments

The company has distinct business segments that contribute to its overall operations. The primary segments include:

Generics: The company operates a significant business in generics that focuses on developing generic pharmaceutical products for global markets. This segment showcases the company's capability in producing cost-effective, high-quality medications that cater to a variety of health needs across different regions.

Branded Pharmaceuticals: In this segment, the company creates and offers branded medications, primarily targeting emerging markets. With therapeutic areas ranging from chronic to acute diseases, the portfolio under this segment is strategically aligned to cater to unique regional health demands.

Specialty: The company is increasingly focusing on specialty pharmaceuticals, which typically require advanced research and development investments. This includes niches such as oncology, respiratory, and dermatology, where the company aims to build a robust portfolio to support ongoing therapeutic innovations.

API (Active Pharmaceutical Ingredients): The company engages in manufacturing APIs, providing vital components for both its finished medicines and for external clients.

Biosimilars: The company also focuses on developing biosimilars, a rapidly evolving segment in the pharmaceutical industry. These are biological products highly like already approved reference products, and the company aims to leverage research advances to deliver effective treatment solutions at lower costs.

Business Strategy

The company adopts a multifaceted business strategy aims at achieving sustainable growth and maintaining a competitive edge in the pharmaceutical landscape.

The company emphasizes innovation as a cornerstone of its strategy. Investing in research and development enables the company to create unique pharmaceutical solutions, responding to healthcare challenges with advanced therapies. Continuous R&D efforts aims at improving current products, and at exploring novel formulations and delivery systems that can enhance patient outcomes.

Another integral aspect of the company's strategy is global expansion. The company targets both developed and emerging market economies, seeking to enhance its global footprint. By understanding regional healthcare needs and regulatory environments, the company strategically positions its products and services to align with local requirements.

Strategically partnering with other industry leaders and research institutions enables the company to maximize its research capabilities while mitigating risks associated with drug development.

Furthermore, the company is committed to enhancing accessibility to medications, adopting practices that address profitability and ensure that essential medicines reach the patients who need them most.

Products and Services

The company boasts a diverse range of products and services that encompass both prescription and over-the-counter medications. The product landscape includes:

Prescription Drugs: The company offers medications across various therapeutic areas such as dermatology, oncology, respiratory diseases, and more, ensuring that healthcare providers have access to effective solutions catering to multiple health conditions.

OTC Products: The company also markets a variety of over-the-counter products that cater to everyday healthcare needs. These products aim at enhancing wellness and managing common ailments, making healthcare accessible to a broader audience.

Specialized Treatments: The company's focus on specialty pharmaceuticals entails developing advanced treatments that address complex diseases. These products often come with accompanying patient support programs to ensure adherence and optimize outcomes.

Generic Formulations: The company provides a wide range of generic formulations that support affordability and accessibility in healthcare. This segment includes generic drugs that are bioequivalent to brand-name drugs, ensuring that patients receive comparable efficacy.

Biosimilars: The company actively developing biosimilars to provide access to high-quality biological drugs at lower costs, fulfilling an essential need in the market.

In addition to products, the company also engages in services such as pharmacovigilance, which involves monitoring the safety of its drugs in the market.

Geographical Markets Served

The company serves a global market, with established operations in numerous countries including the United States, various European nations, India, and several emerging markets.

Customers

The company serves a broad spectrum of customers, including hospitals, healthcare providers, pharmacies, and end consumers. The company caters to both public and private sectors, thereby reaching diverse customer categories.

Sales and Marketing

The company employs a multi-channel marketing strategy that encompasses both traditional and digital platforms. The company's marketing approach aims at increasing brand awareness and educating healthcare professionals and consumers about its products.

Distribution channels include direct selling to healthcare institutions, partnerships with distributors, and online channels.

History

Glenmark Pharmaceuticals Limited was founded in 1977. The company was incorporated in 1977.

Glenmark Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2025) **TOP 3 Markets:** 1. **India:** 30% 2. **USA:** 25% 3. **Europe:** 15% Glenmark Pharmaceuticals Limited generates all its sales from the pharmaceutical industry. The company operates in various therapeutic areas, including dermatology, oncology, and respirato...

At which locations are the company’s products manufactured?

**Production Sites:** India, USA, Argentina, Brazil, Czech Republic Glenmark Pharmaceuticals Limited operates several production facilities worldwide. The majority of production takes place in India, where the company has multiple plants. In addition, Glenmark has production sites in the USA, Argen...

What strategy does Glenmark Pharmaceuticals pursue for future growth?

**Revenue Growth:** Estimated 8-10% annually (2025) Glenmark Pharmaceuticals Limited is pursuing a growth strategy based on several pillars. An essential component is the expansion into international markets, especially in emerging countries, where the company expects increasing demand for generic...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients **Countries of origin:** China, India, Europe Glenmark Pharmaceuticals Limited mainly imports active pharmaceutical ingredients (APIs) and excipients that are necessary for the production of their products. A significant...

How strong is the company’s competitive advantage?

**Market Share:** 3.5% in the Indian pharmaceutical market (2024) **R&D Expenses:** 9% of revenue (2024) **EBITDA Margin:** 18% (2024) Glenmark Pharmaceuticals Limited has a moderate competitive advantage in the pharmaceutical sector, especially in the Indian market. The company benefits...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (estimated for 2025 based on trends from 2023) **Insider Buys/Sells:** No significant transactions in recent months (estimated for 2025) The institutional investor share in Glenmark Pharmaceuticals Limited has typically ranged between 40% and 50%...

What percentage market share does Glenmark Pharmaceuticals have?

**Market share of Glenmark Pharmaceuticals:** 2.5% (estimated, 2025) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8.5% 2. **Dr. Reddy's Laboratories Ltd.:** 7.0% 3. **Cipla Ltd.:** 6.5% 4. **Aurobindo Pharma Ltd.:** 5.5% 5. **Lupin Ltd.:** 5.0% 6. **Z...

Is Glenmark Pharmaceuticals stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Research and Development Ratio:** 9.2% of revenue (2024) **Net Debt Ratio:** 0.6 (2024) Glenmark Pharmaceuticals Limited shows a solid revenue growth of 8.5% in 2024, indicating strong demand for its products and effective market expansion. Investments in research...

Does Glenmark Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.8% (2024) **Dividend history:** Regular payouts over the last 5 years Glenmark Pharmaceuticals Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The dividend yield of 1.8% in 2024 shows that the company is committed to...

New support ticket

Explore

Glenmark Pharmaceuticals Stock Value

Glenmark Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Glenmark Pharmaceuticals do?

Glenmark Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Glenmark Pharmaceuticals Stock Value

Glenmark Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Glenmark Pharmaceuticals do?

Glenmark Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.